Cell therapy weekly: European Commission grants marketing authorization for Skysona™ gene therapy for patients with CALD

This week: the European Commission has granted marketing authorization for a gene therapy (Skysona™) for patients with early cerebral adrenoleukodystrophy, the US FDA has granted Fast Track Designation for DA01 stem cell therapy for advanced Parkinson’s disease, and BioNTech has entered into a purchase agreement with Kite Pharma for their solid tumor neoantigen T-cell receptor R&D platform. The news highlights: European Commission grants marketing authorization for Skysona™ gene therapy for patients with CALD US FDA grants Fast Track Designation for DA01 stem cell therapy in the treatment of advanced Parkinson’s BioNTech acquires neoantigen TCR cell therapy platform from Kite, strengthening...